An unusual cause of acute kidney injury due to oxalate nephropathy in systemic scleroderma

Clinical Nephrology

Volumn 84, Issue 2, 2015, Pages 111-115

  Mascio, Heather M ^a   Joya, Christie A ^a   Plasse, Richard A ^a   Baker, Thomas P ^b   Flessner, Michael F ^c   Nee, Robert ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b Department of Medicine Walter Reed National Military Medical Center ^*  (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Acute kidney injury; Oxalate nephropathy; Scleroderma

Indexed keywords

CALCIUM OXALATE; CREATININE; METHYLPREDNISOLONE SODIUM SUCCINATE; PREDNISONE; RIFAXIMIN; NUCLEIC ACID SYNTHESIS INHIBITOR; RIFAMYCIN;

ACUTE KIDNEY FAILURE; AFRICAN AMERICAN; AGED; ANOREXIA; ARTICLE; BLOOD PRESSURE; CASE REPORT; CLINICAL FEATURE; CORTICOSTEROID THERAPY; CREATININE URINE LEVEL; FEMALE; HEMODIALYSIS; HOSPICE CARE; HUMAN; HYPONATREMIA; INTENSIVE CARE; INTESTINE ABSORPTION; INTESTINE PSEUDOOBSTRUCTION; INTESTINE TRANSIT TIME; INTRATUBULAR BIREFRINGENT CRYSTAL; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TUBULE DAMAGE; MENTAL HEALTH; NUTRITIONAL STATUS; OXALATE NEPHROPATHY; SMALL INTESTINAL BACTERIAL OVERGROWTH; SMALL INTESTINE DISEASE; SYSTEMIC SCLEROSIS; TREATMENT DURATION; TREATMENT RESPONSE; URINALYSIS; ACUTE KIDNEY INJURY; CHEMISTRY; COMPLICATION; DRUG EFFECTS; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRANSIT; INTESTINAL DISEASES; INTESTINAL PSEUDO-OBSTRUCTION; METABOLISM; MICROBIOLOGY; NEPHRITIS, INTERSTITIAL; PHYSIOLOGY; SMALL INTESTINE;

ACUTE KIDNEY INJURY; AGED; CALCIUM OXALATE; FEMALE; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRANSIT; HUMANS; INTESTINAL ABSORPTION; INTESTINAL DISEASES; INTESTINAL PSEUDO-OBSTRUCTION; INTESTINE, SMALL; NEPHRITIS, INTERSTITIAL; NUCLEIC ACID SYNTHESIS INHIBITORS; RIFAMYCINS; SCLERODERMA, SYSTEMIC;

EID: 84941212327     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN108406     Document Type: Article

References (27)

1. Hudson M, Fritzler MJ. Diagnostic criteria of systemic sclerosis. J Autoimmun. 2014; 48-49: 38-41. CrossRef PubMed
2. Shanmugam VK, Steen VD. Renal disease in scleroderma: an update on evaluation, risk stratification, pathogenesis and management. Curr Opin Rheumatol. 2012; 24: 669-676. CrossRef PubMed
3. Steen VD, Syzd A, Johnson JP, Greenberg A, Medsger TA Jr. Kidney disease other than renal crisis in patients with diffuse scleroderma. J Rheumatol. 2005; 32: 649-655. PubMed
4. Penn H, Denton CP. Diagnosis, management and prevention of scleroderma renal disease. Curr Opin Rheumatol. 2008; 20: 692-696. CrossRef PubMed
5. Kamen DL, Wigley FM, Brown AN. Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis in scleroderma - a different kind of renal crisis. J Rheumatol. 2006; 33: 1886-1888. PubMed
6. Maes B, Van Mieghem A, Messiaen T, Kuypers D, Van Damme B, Vanrenterghem Y. Limited cutaneous systemic sclerosis associated with MPOANCA positive renal small vessel vasculitis of the microscopic polyangiitis type. Am J Kidney Dis. 2000; 36: E16. CrossRef PubMed
7. Caron M, Hudson M, Baron M, Nessim S, Steele R, Pope J, Markland J, Robinson D, Jones N, Khalidi N, Docherty P, Kaminska E, Masetto A, Sutton E, Mathieu J-P, Ligier S, Grodzicky T, Thorne C, LeClercq S, Fritzler M; Canadian Scleroderma Research Group. Longitudinal study of renal function in systemic sclerosis. J Rheumatol. 2012; 39: 1829-1834. CrossRef PubMed
8. Cartery C, Faguer S, Karras A, Cointault O, Buscail L, Modesto A, Ribes D, Rostaing L, Chauveau D, Giraud P. Oxalate nephropathy associated with chronic pancreatitis. Clin J Am Soc Nephrol. 2011; 6: 1895-1902. CrossRef PubMed
9. Herlitz LC, D'Agati VD, Markowitz GS. Crystalline nephropathies. Arch Pathol Lab Med. 2012; 136: 713-720. CrossRef PubMed
10. Robijn S, Hoppe B, Vervaet BA, D'Haese PC, Verhulst A. Hyperoxaluria: a gut-kidney axis? Kidney Int. 2011; 80: 1146-1158. CrossRef PubMed
11. Savarino E, Mei F, Parodi A, Ghio M, Furnari M, Gentile A, Berdini M, Di Sario A, Bendia E, Bonazzi P, Scarpellini E, Laterza L, Savarino V, Gasbarrini A. Gastrointestinal motility disorder assessment in systemic sclerosis. Rheumatology (Oxford). 2013; 52: 1095-1100. CrossRef PubMed
12. Ojetti V, Lauritano EC, Barbaro F, Migneco A, Ainora ME, Fontana L, Gabrielli M, Gasbarrini A. Rifaximin pharmacology and clinical implications. Expert Opin Drug Metab Toxicol. 2009; 5: 675-682. CrossRef PubMed
13. Kelly JP, Curhan GC, Cave DR, Anderson TE, Kaufman DW. Factors related to colonization with Oxalobacter formigenes in U.S. adults. J Endourol. 2011; 25: 673-679. CrossRef PubMed
14. Siva S, Barrack ER, Reddy GP, Thamilselvan V, Thamilselvan S, Menon M, Bhandari M. A critical analysis of the role of gut Oxalobacter formigenes in oxalate stone disease. BJU Int. 2009; 103: 18-21. CrossRef PubMed
15. Jiang J, Knight J, Easter LH, Neiberg R, Holmes RP, Assimos DG. Impact of dietary calcium and oxalate, and Oxalobacter formigenes colonization on urinary oxalate excretion. J Urol. 2011; 186: 135-139. CrossRef PubMed
16. Siener R, Bangen U, Sidhu H, Hönow R, von Unruh G, Hesse A. The role of Oxalobacter formigenes colonization in calcium oxalate stone disease. Kidney Int. 2013; 83: 1144-1149. CrossRef PubMed
17. Nikou GC, Toumpanakis C, Katsiari C, Charalambopoulos D, Sfikakis PP. Treatment of small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven patients. J Clin Rheumatol. 2007; 13: 119-123. CrossRef PubMed
18. Hautmann RE. The stomach: a new and powerful oxalate absorption site in man. J Urol. 1993; 149: 1401-1404. PubMed
19. Morgan SH, Purkiss P, Watts RW, Mansell MA. Oxalate dynamics in chronic renal failure. Comparison with normal subjects and patients with primary hyperoxaluria. Nephron. 1987; 46: 253-257. CrossRef PubMed
20. Clifford-Mobley O, Tims C, Rumsby G. The comparability of oxalate excretion and oxalate: creatinine ratio in the investigation of primary hyperoxaluria: review of data from a referral centre. Ann Clin Biochem. 2014; Epub ahead of print. Cross-RefPubMed
21. Matos V, Van Melle G, Werner D, Bardy D, Guignard JP. Urinary oxalate and urate to creatinine ratios in a healthy pediatric population. Am J Kidney Dis. 1999; 34: e1. CrossRef PubMed
22. Mpofu S, Rhodes JM, Mpofu CM, Moots RJ. An unusual cause of acute renal failure in systemic sclerosis. Ann Rheum Dis. 2003; 62: 1133-1134. CrossRef PubMed
23. Kurts C. A crystal-clear mechanism of chronic kidney disease. Kidney Int. 2013; 84: 859-861. CrossRef PubMed
24. Knauf F, Asplin JR, Granja I, Schmidt IM, Moeckel GW, David RJ, Flavell RA, Aronson PS. NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy. Kidney Int. 2013; 84: 895-901. CrossRef PubMed
25. Bobrowski AE, Langman CB. Hyperoxaluria and systemic oxalosis: current therapy and future directions. Expert Opin Pharmacother. 2006; 7: 1887-1896. CrossRef PubMed
26. Harper J, Mansell MA. Treatment of enteric hyperoxaluria. Postgrad Med J. 1991; 67: 219-222. CrossRef PubMed
27. Hueppelshaeuser R, von Unruh GE, Habbig S, Beck BB, Buderus S, Hesse A, Hoppe B. Enteric hyperoxaluria, recurrent urolithiasis, and systemic oxalosis in patients with Crohn's disease. Pediatr Nephrol. 2012; 27: 1103-1109. CrossRef PubMed